BCI as a Predictive Biomarker for Extended Endocrine Therapy Benefit

Guideline Updates for Extended Endocrine Therapy Decision-Making in HR+, Early-Stage Breast CancerПодробнее

Harnessing the Power of Predictive BiomarkersПодробнее

Partnering to Provide Personalized Care: Patient Selection for Extended Endocrine TherapyПодробнее

The Predictive Power of the Breast Cancer Index (H/I) Biomarker-SABCS 2022Подробнее

Guideline Updates for Extended Endocrine Therapy Decision-Making in HR+, Early-Stage Breast CancerПодробнее

Composite biomarkers predictive of palbociclib + endocrine treatment benefit in early breast cancerПодробнее

Standardizing Extended Endocrine Therapy RecommendationsПодробнее

The Role of BCI in Extended Endocrine Therapy Decision MakingПодробнее

BCI: A Unique, Guideline-Recognized Test to Predict Benefit of Extended Endocrine TherapyПодробнее

JADPRO Live 2023 - Standardizing Extended Endocrine Therapy Decision-MakingПодробнее

Utilizing the Appropriate Tool for Extended Endocrine Therapy Decision-Making: BCI vs Oncotype DxПодробнее

Updates in Extended Endocrine Therapy for HR+ Breast Cancer | ASCO21 & National Practice GuidelinesПодробнее

The BCI prognostic model for late relapse breast cancerПодробнее

Breast Cancer Index, Extended Endocrine Therapy | Elizabeth Ott, PA | 2022 West Oncology APP UpdatesПодробнее

What is the Difference Between Prognostic Information and Predictive Information?Подробнее

Brock Schroeder Discusses BCI Findings in ER+ Breast CancerПодробнее

Breast Cancer Index: The Endocrine BiomarkerПодробнее

Adjuvant/Neoadjuvant Therapy for Breast Cancer: Updates and Molecular Predictors of BenefitПодробнее

Role of Advanced Practitioners in Extended Endocrine Therapy Decision-Making (or BCI)Подробнее